Advisory Board on Radiation and Worker Health (ABRWH or Advisory Board), National Institute for Occupational Safety and Health (NIOSH), 62240-62241 [2012-25097]
Download as PDF
<![CDATA[
62240
Federal Register / Vol. 77, No. 198 / Friday, October 12, 2012 / Notices
wreier-aviles on DSK5TPTVN1PROD with NOTICES
care costs, higher quality of care, and
improved service offerings. Left
unremedied, the proposed acquisition
likely would cause anticompetitive
harm by enabling UHS to profit by
unilaterally raising the reimbursement
rates negotiated with commercial health
plans. These costs are ultimately borne
by consumers in the form of higher
premiums, co-pays, and other out-ofpocket costs. The loss of competition
also reduces UHS?s incentive to
improve quality and provide better
service.
New entry or expansion is unlikely to
deter or counteract the anticompetitive
effects of the proposed acquisition.
While regulatory barriers to opening a
new psychiatric facility or unit are
lower in Texas and New Mexico than in
other states (e.g., there are no Certificate
of Need regulations in either state), local
zoning regulations, Medicaid and
Medicare certifications, and the need to
develop strong relationships with local
patient referral sources hinder the
ability of firms to enter the market. Cuts
to Medicaid funding may also affect the
financial incentive of a provider to offer
inpatient psychiatric services. Thus, it is
unlikely that new entry or expansion
sufficient to achieve a significant market
impact will occur in a timely manner.
IV. The Proposed Consent Agreement
The proposed Consent Agreement
wholly remedies the anticompetitive
effects in the El Paso/Santa Teresa
market by requiring UHS to divest Peak,
located in Santa Teresa, New Mexico,
and its associated operations and
businesses within six months after
issuance of the Decision and Order. The
potential acquirer of Peak is subject to
prior approval of the Commission. The
Consent Agreement also provides that, if
Peak is not sold to an approved acquirer
within six months, a Divestiture Trustee
will be appointed and empowered to
divest both Peak and Mesilla Valley.
The purpose of this provision is to
address the uncertainty of whether Peak
alone is sufficient to attract an acquirer
that would compete as effectively as
UHS competed prior to the merger.
Until completion of the requisite
divestiture(s), UHS is required to abide
by the Order to Hold Separate and
Maintain Assets, which includes a
requirement that UHS hold Peak
separate from its other businesses and
facilities, and a requirement to take all
actions necessary to maintain the
economic viability, marketability, and
competitiveness of the both the Peak
and Mesilla Valley assets. The Consent
Agreement also requires UHS to provide
transitional services to the approved
acquirer for one year, as needed to assist
VerDate Mar<15>2010
13:59 Oct 11, 2012
Jkt 229001
the acquirer with operating the divested
assets as a viable and ongoing business.
In addition, the proposed order allows
the Commission to appoint a Hold
Separate Trustee to oversee UHS’s
compliance with the Order to Hold
Separate and Maintain Assets. Finally,
the proposed order contains a ten-year
prior notice requirement for acquisitions
of acute inpatient psychiatric service
providers in the local area, as well as
compliance reporting requirements.
The sole purpose of this analysis is to
facilitate public comment on the
Consent Agreement. This analysis does
not constitute an official interpretation
of the Consent Agreement or modify its
terms in any way.
By direction of the Commission.
Donald S. Clark,
Secretary.
[FR Doc. 2012–25140 Filed 10–11–12; 8:45 am]
BILLING CODE 6750–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Disease, Disability, and Injury
Prevention and Control Special
Emphasis Panel: Notice of Charter
Renewal
This gives notice under the Federal
Advisory Committee Act (Pub. L. 92–
463) of October 6, 1972, that Disease,
Disability, and Injury Prevention and
Control Special Emphasis Panel, Centers
for Disease Control and Prevention,
Department of Health and Human
Services, has been renewed for a 2-year
period through September 18, 2014.
For information, contact John
Kastenbauer, J.D., Designated Federal
Officer, Disease, Disability, and Injury
Prevention and Control Special
Emphasis Panel, Centers for Disease
Control and Prevention, Department of
Health and Human Services, 1600
Clifton Road NE., Mailstop E11, Atlanta,
Georgia 30333, telephone (770)488–
4778 or fax (770)488–4890.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities, for both the
Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
PO 00000
Frm 00030
Fmt 4703
Sfmt 4703
Dated: October 5, 2012.
John Kastenbauer,
Acting Director, Management Analysis and
Services Office, Centers for Disease Control
and Prevention.
[FR Doc. 2012–25096 Filed 10–11–12; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Advisory Board on Radiation and
Worker Health (ABRWH or Advisory
Board), National Institute for
Occupational Safety and Health
(NIOSH)
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention announces the
following meeting of the
aforementioned committee:
Time and Date: 11:00 a.m.–3:00 p.m.,
November 5, 2012.
Place: Audio Conference Call via FTS
Conferencing. The USA toll-free, dial-in
number is 1–866–659–0537 and the pass
code is 9933701.
Status: Open to the public, but
without a verbal public comment
period. Written comment should be
provided to the contact person below in
advance of the meeting.
Background: The Advisory Board was
established under the Energy Employees
Occupational Illness Compensation
Program Act of 2000 to advise the
President on a variety of policy and
technical functions required to
implement and effectively manage the
new compensation program. Key
functions of the Advisory Board include
providing advice on the development of
probability of causation guidelines,
which have been promulgated by the
Department of Health and Human
Services (HHS) as a final rule; advice on
methods of dose reconstruction, which
have also been promulgated by HHS as
a final rule; advice on the scientific
validity and quality of dose estimation
and reconstruction efforts being
performed for purposes of the
compensation program; and advice on
petitions to add classes of workers to the
Special Exposure Cohort (SEC).
In December 2000, the President
delegated responsibility for funding,
staffing, and operating the Advisory
Board to HHS, which subsequently
delegated this authority to the CDC.
NIOSH implements this responsibility
for CDC. The charter was issued on
August 3, 2001, renewed at appropriate
E:\FR\FM\12OCN1.SGM
12OCN1
Federal Register / Vol. 77, No. 198 / Friday, October 12, 2012 / Notices
wreier-aviles on DSK5TPTVN1PROD with NOTICES
intervals, most recently, August 3, 2011,
and will expire on August 3, 2013.
Purpose: This Advisory Board is
charged with (a) providing advice to the
Secretary, HHS, on the development of
guidelines under Executive Order
13179; (b) providing advice to the
Secretary, HHS, on the scientific
validity and quality of dose
reconstruction efforts performed for this
program; and c) upon request by the
Secretary, HHS, advising the Secretary
on whether there is a class of employees
at any Department of Energy facility
who were exposed to radiation but for
whom it is not feasible to estimate their
radiation dose, and on whether there is
reasonable likelihood that such
radiation doses may have endangered
the health of members of this class.
Matters to be Discussed: The agenda
for the conference call includes: SEC
Petition for Battelle Laboratories—King
Avenue (Columbus, Ohio);
Subcommittee and Work Group
Updates; SEC Petition Evaluations
Update for the December 2012 Advisory
Board Meeting; Plans for December 2012
Advisory Board Meeting; and Advisory
Board Correspondence.
The agenda is subject to change as
priorities dictate. Because there is not
an oral public comment period, written
comments may be submitted. Any
written comments received will be
included in the official record of the
meeting and should be submitted to the
contact person below in advance of the
meeting.
Contact Person for More Information:
Theodore M. Katz, M.P.A., Executive
Secretary, NIOSH, CDC, 1600 Clifton
Road NE., Mailstop: E–20, Atlanta,
Georgia 30333, Telephone (513)533–
6800, Toll Free 1–800–CDC–INFO,
Email ocas@cdc.gov.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities, for both the
Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Dated: October 5, 2012.
John Kastenbauer,
Acting Director, Management Analysis and
Services Office, Centers for Disease Control
and Prevention.
[FR Doc. 2012–25097 Filed 10–11–12; 8:45 am]
BILLING CODE 4163–18–P
VerDate Mar<15>2010
13:59 Oct 11, 2012
Jkt 229001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Medicare & Medicaid
Services
[Document Identifier: CMS–10237 and CMS–
10137]
Agency Information Collection
Activities: Submission for OMB
Review; Comment Request
Centers for Medicare &
Medicaid Services, HHS.
In compliance with the requirement
of section 3506(c)(2)(A) of the
Paperwork Reduction Act of 1995, the
Centers for Medicare & Medicaid
Services (CMS), Department of Health
and Human Services, is publishing the
following summary of proposed
collections for public comment.
Interested persons are invited to send
comments regarding this burden
estimate or any other aspect of this
collection of information, including any
of the following subjects: (1) The
necessity and utility of the proposed
information collection for the proper
performance of the Agency’s function;
(2) the accuracy of the estimated
burden; (3) ways to enhance the quality,
utility, and clarity of the information to
be collected; and (4) the use of
automated collection techniques or
other forms of information technology to
minimize the information collection
burden.
1. Type of Information Collection
Request: Revision of a currently
approved collection. Title of
Information Collection: Part C Medicare
Advantage and 1876 Cost Plan
Expansion Application; Use: Collection
of this information is mandated in Part
C of the Medicare Prescription Drug,
Improvement and Modernization Act of
2003 (MMA) in Subpart K of 42 CRF 422
entitled ‘‘Contracts with Medicare
Advantage Organizations.’’ In addition,
the Medicare Improvements for Patients
and Providers Act of 2008 (MIPPA)
amended titles XVII and XIX of the
Social Security Act to improve the
Medicare program.
In general, coverage for the
prescription drug benefit is provided
through prescription drug plans (PDPs)
that offer drug-only coverage or through
Medicare Advantage (MA) organizations
that offer integrated prescription drug
and health care products (MA–PD
plans). PDPs must offer a basic drug
benefit. Medicare Advantage
Coordinated Care Plans (MA–CCPs)
either must offer a basic benefit or may
offer broader coverage for no additional
cost. Medicare Advantage Private Fee
for Service Plans (MA–PFFS) may
AGENCY:
PO 00000
Frm 00031
Fmt 4703
Sfmt 4703
62241
choose to offer enrollees a Part D
benefit. Employer Group Plans may also
provide Part D benefits. If any of the
contracting organizations meet basic
requirements, they may also offer
supplemental benefits through
enhanced alternative coverage for an
additional premium.
Organizations wishing to provide
healthcare services under MA and/or
MA–PD plans must complete an
application, file a bid, and receive final
approval from CMS. Existing MA plans
may request to expand their contracted
service area by completing the Service
Area Expansion (SAE) application.
Applicants may offer a local MA plan in
a county, a portion of a county (i.e., a
partial county) or multiple counties.
Applicants may offer a MA regional
plan in one or more of the 26 MA
regions.
Since the publication of the 60-day
notice, the information collection
request has been revised to provide
clarification to applicants, to ensure
consistency throughout the entire
application, and to reduce confusion
among applicants. As a result of those
changes, the overall burden associated
with the collection has decreased from
22,995 to 21,581 hours. Form Number:
CMS–10237 (OCN 0938–0935).
Frequency: Yearly. Affected Public:
Private Sector (Business or other forprofits, Not-for-profit institutions).
Number of Respondents: 566. Total
Annual Responses: 566. Total Annual
Hours: 21,581. (For policy questions
regarding this collection contact Barbara
Gullick at 410–786–0563. For all other
issues call 410–786–1326.)
2. Type of Information Collection
Request: Revision of a currently
approved collection; Title: Application
for New and Expanding Medicare
Prescription Drug Plans and Medicare
Advantage Prescription Drug (MA–PD),
including Cost Plans and Employer
Group Waiver Plans; Use: The Medicare
Prescription Drug Benefit program was
established by section 101 of the
Medicare Prescription Drug,
Improvement, and Modernization Act of
2003 (MMA) and is codified in section
1860D of the Social Security Act (the
Act). Section 101 of the MMA amended
Title XVIII of the Social Security Act by
redesignating Part D as Part E and
inserting a new Part D, which
establishes the voluntary Prescription
Drug Benefit Program (‘‘Part D’’). The
MMA was amended on July 15, 2008 by
the enactment of the Medicare
Improvements for Patients and
Providers Act of 2008 (MIPPA), on
March 23, 2010 by the enactment of the
Patient Protection and Affordable Care
Act and on March 30, 2010 by the
E:\FR\FM\12OCN1.SGM
12OCN1
]]>Agencies
[Federal Register Volume 77, Number 198 (Friday, October 12, 2012)]
[Notices]
[Pages 62240-62241]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-25097]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Advisory Board on Radiation and Worker Health (ABRWH or Advisory
Board), National Institute for Occupational Safety and Health (NIOSH)
In accordance with section 10(a)(2) of the Federal Advisory
Committee Act (Pub. L. 92-463), the Centers for Disease Control and
Prevention announces the following meeting of the aforementioned
committee:
Time and Date: 11:00 a.m.-3:00 p.m., November 5, 2012.
Place: Audio Conference Call via FTS Conferencing. The USA toll-
free, dial-in number is 1-866-659-0537 and the pass code is 9933701.
Status: Open to the public, but without a verbal public comment
period. Written comment should be provided to the contact person below
in advance of the meeting.
Background: The Advisory Board was established under the Energy
Employees Occupational Illness Compensation Program Act of 2000 to
advise the President on a variety of policy and technical functions
required to implement and effectively manage the new compensation
program. Key functions of the Advisory Board include providing advice
on the development of probability of causation guidelines, which have
been promulgated by the Department of Health and Human Services (HHS)
as a final rule; advice on methods of dose reconstruction, which have
also been promulgated by HHS as a final rule; advice on the scientific
validity and quality of dose estimation and reconstruction efforts
being performed for purposes of the compensation program; and advice on
petitions to add classes of workers to the Special Exposure Cohort
(SEC).
In December 2000, the President delegated responsibility for
funding, staffing, and operating the Advisory Board to HHS, which
subsequently delegated this authority to the CDC. NIOSH implements this
responsibility for CDC. The charter was issued on August 3, 2001,
renewed at appropriate
[[Page 62241]]
intervals, most recently, August 3, 2011, and will expire on August 3,
2013.
Purpose: This Advisory Board is charged with (a) providing advice
to the Secretary, HHS, on the development of guidelines under Executive
Order 13179; (b) providing advice to the Secretary, HHS, on the
scientific validity and quality of dose reconstruction efforts
performed for this program; and c) upon request by the Secretary, HHS,
advising the Secretary on whether there is a class of employees at any
Department of Energy facility who were exposed to radiation but for
whom it is not feasible to estimate their radiation dose, and on
whether there is reasonable likelihood that such radiation doses may
have endangered the health of members of this class.
Matters to be Discussed: The agenda for the conference call
includes: SEC Petition for Battelle Laboratories--King Avenue
(Columbus, Ohio); Subcommittee and Work Group Updates; SEC Petition
Evaluations Update for the December 2012 Advisory Board Meeting; Plans
for December 2012 Advisory Board Meeting; and Advisory Board
Correspondence.
The agenda is subject to change as priorities dictate. Because
there is not an oral public comment period, written comments may be
submitted. Any written comments received will be included in the
official record of the meeting and should be submitted to the contact
person below in advance of the meeting.
Contact Person for More Information: Theodore M. Katz, M.P.A.,
Executive Secretary, NIOSH, CDC, 1600 Clifton Road NE., Mailstop: E-20,
Atlanta, Georgia 30333, Telephone (513)533-6800, Toll Free 1-800-CDC-
INFO, Email ocas@cdc.gov.
The Director, Management Analysis and Services Office, has been
delegated the authority to sign Federal Register notices pertaining to
announcements of meetings and other committee management activities,
for both the Centers for Disease Control and Prevention and the Agency
for Toxic Substances and Disease Registry.
Dated: October 5, 2012.
John Kastenbauer,
Acting Director, Management Analysis and Services Office, Centers for
Disease Control and Prevention.
[FR Doc. 2012-25097 Filed 10-11-12; 8:45 am]
BILLING CODE 4163-18-P
